(4-(benzo[d]thiazol-2-yl)phenyl)methanamine | 34211-04-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: (4-(benzo[d]thiazol-2-yl)phenyl)methanamine
• 英文别名: 4-benzothiazol-2-yl-benzylamine；1-[4-(1,3-Benzothiazol-2-yl)phenyl]methanamine；[4-(1,3-benzothiazol-2-yl)phenyl]methanamine
• CAS: 34211-04-6
• 化学式: C₁₄H₁₂N₂S
• mdl: MFCD05238792
• 分子量: 240.329
• InChiKey: YOAAMMPAUQNJOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-(benzo[d]thiazol-2-yl)phenyl)methanamine 在 氯化亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 8.0h， 生成
  参考文献：
  名称：

  氮杂二硫代氮原子和苯基之间的亚甲基对[FeFe]-氢化酶模型配合物亲脂性的影响

  摘要：

  合成了具有功能性苄基部分的[FeFe]-加氢酶模拟物4，该功能性苄基部分与氮杂二硫醇盐配体共价连接。同时研究了4和一个苯基取代的类似物（编码为3）的结构，质子化和电化学性质，以探讨桥头氮原子和官能苯基部分之间的亚甲基对模型配合物亲脂性的影响。X射线单晶衍射分析表明3和4的氮原子具有sp 2和sp 3-杂交，分别。虽然被阻止的分子中的光驱动的电子传递4中，SP 3的杂化的氮原子的4可在质子酸的存在下被质子化，得到[ 4（NH）] +阳离子。所产生的正电荷可以在大约200℃处降低。-1.2 V与Fc / Fc +相比，具有明显的电催化质子还原活性，而3催化的质子还原发生在约200℃ 。-1.45 V.的催化质子减少3和4随后ECCE和CECE机制，分别。值得注意的是4的潜力 明显地阳极移动并接近于天然酶催化的质子还原。

  DOI：

  10.1007/s11696-017-0187-7
• 作为产物：
  描述：

  N-(4-benzothiazol-2-yl-benzyl)-phthalimide 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 (4-(benzo[d]thiazol-2-yl)phenyl)methanamine
  参考文献：
  名称：

  抗菌剂。1.苯并噻唑基苄胺。

  摘要：

  DOI：

  10.1021/jm00294a024

文献信息

• Multifunctional iron-chelators with protective roles against neurodegenerative diseases
  作者：Andreia Nunes、Sérgio M. Marques、Catarina Quintanova、Diana F. Silva、Sandra M. Cardoso、Sílvia Chaves、M. Amélia Santos

  DOI：10.1039/c3dt50406a

  日期：——

  anti-acetylcholinesterase activity. Therefore, 3-hydroxy-4-pyridinone (3,4-HP) and benzothiazole molecular moieties were selected as starting frameworks due to their well known affinity for iron and Aβ peptides, respectively. The linkers between these two main functional groups were selected on the basis of virtual screening, so that the final molecule could further inhibit the acetylcholinesterase, responsible for the

  阿尔茨海默氏病（AD）的多因素性质以及缺乏疾病改良药物，使得开发新的多功能药物成为一种有吸引力的治疗策略。考虑到AD患者大脑的特点，例如乙酰胆碱水平低，蛋白质错误折叠和相关的β-淀粉样蛋白（Aβ）聚集，氧化应激和金属动态异常，我们开发了一系列化合物，这些化合物合并了三种不同的方法：金属减毒，抗Aβ聚集和抗乙酰胆碱酯酶活性。所以，3-羟基-4-吡啶酮 （3,4-HP）和 苯并噻唑由于分子部分分别对铁和Aβ肽的熟知的亲和力，因此选择分子部分作为起始框架。在虚拟筛选的基础上选择了这两个主要功能基团之间的接头，以便最终分子可以进一步抑制乙酰胆碱酯酶，这是造成胆碱能丧失的原因。我们在本文中描述了新杂化化合物的设计和合成，然后评估了溶液的性质，即铁螯合和抗氧化能力。对这些化合物具有抑制AChE的能力以及自身和锌介导的Aβ1–42聚集的能力进行了生物测定。最后，我们评估了它们对Aβ42应激神经元细胞活力的影响。
• NOVEL COMPOUND FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE AND COMPOSITION CONTAINING SAME
  申请人：Industry-Academic Cooperation Foundation Yonsei University

  公开号：EP3431472A2

  公开（公告）日：2019-01-23

  The present invention relates to a novel compounds for inhibiting nicotinamide phosphoribosyltransferase (NamPT), a composition comprising the same, and various uses thereof.

  本发明涉及一种用于抑制烟酰胺磷酸核糖转移酶（NamPT）的新型化合物、包含该化合物的组合物及其各种用途。
• Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same
  申请人：CHECKMATE THERAPEUTICS INC.

  公开号：US11078195B2

  公开（公告）日：2021-08-03

  The present invention relates to a novel compounds for inhibiting nicotinamide phosphoribosyltransferase (NamPT), a composition comprising the same, and various uses thereof.

  本发明涉及一种用于抑制烟酰胺磷酸核糖转移酶（NamPT）的新型化合物、包含该化合物的组合物及其各种用途。
• Design, synthesis and neuroprotective evaluation of novel tacrine–benzothiazole hybrids as multi-targeted compounds against Alzheimer’s disease
  作者：Rangappa S. Keri、Catarina Quintanova、Sérgio M. Marques、A. Raquel Esteves、Sandra M. Cardoso、M. Amélia Santos

  DOI：10.1016/j.bmc.2013.05.028

  日期：2013.8

  Alzheimer's disease (AD) is a multifactorial disorder with several target proteins contributing to its etiology. In search for multifunctional anti-AD drug candidates, taking into account that the acetylcholinesterase (AChE) and beta-amyloid (A beta) aggregation are particularly important targets for inhibition, the tacrine and benzothiazole (BTA) moieties were conjugated with suitable linkers in a novel series of hybrids. The designed compounds (7a-7e) were synthesized and in vitro as well as in ex vivo evaluated for their capacity for the inhibition of acetylcholinesterase (AChE) and A beta self-induced aggregation, and also for the protection of neuronal cells death (SHSY-5Y cells, AD and MCI cybrids). All the tacrine-BTA hybrids displayed high in vitro activities, namely with IC50 values in the low micromolar to sub-micromolar concentration range towards the inhibition of AChE, and high percentages of inhibition of the self-induced A beta aggregation. Among them, compound 7a, with the shortest linker, presented the best inhibitory activity of AChE (IC50 = 0.34 mu M), while the highest activity as anti-A beta(42) self-aggregation, was evidenced for compound 7b (61.3%, at 50 mu M. The docking studies demonstrated that all compounds are able to interact with both catalytic active site (CAS) and peripheral anionic site (PAS) of AChE. Our results show that compounds 7d and 7e improved cell viability in cells treated with A beta(42) peptide. Overall, these multi-targeted hybrid compounds appear as promising lead compounds for the treatment of Alzheimer's disease. (C) 2013 Elsevier Ltd. All rights reserved.
• [EN] NOVEL COMPOUND FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE AND COMPOSITION CONTAINING SAME<br/>[FR] NOUVEAU COMPOSÉ POUR INHIBER LA NICOTINAMIDE PHOSPHORIBOSYLTRANSFÉRASE ET COMPOSITION CONTENANT LE NOUVEAU COMPOSÉ<br/>[KO] 니코틴아미드 포스포리보실트랜스퍼라제 억제용 신규 화합물 및 이를 포함하는 조성물
  申请人：INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIV

  公开号：WO2017160116A2

  公开（公告）日：2017-09-21

  본 발명은 니코틴아미드 포스포리보실트랜스퍼라제(Nicotinamide phosphoribosyltransferase, NamPT) 억제용 신규 화합물과 이를 포함하는 조성물 및 이의 다양한 용도에 관한 것이다.